ARMGO Pharma is developing a novel drug based on a new strategy for treating muscle weakness and degeneration in Duchenne MD, Becker MD and potentially other muscle disorders

posted on April 17, 2013 - 2:30am
MDA has awarded $1 million to biopharmaceutical company ARMGO Pharma for development of a new strategy for treating Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).

New content is being added every day. Please check back again.